Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / LifeSci Capital
Entity

LifeSci Capital

Tracked across 13 events · 106 articles · First seen Apr 01, 2026 · Last active Aug 07, 2026

Sentiment
17
Attention
4
Events
13
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (13)
2 50
Business
Apnimed IPO on Nasdaq
Impact: LifeSci Capital served as a joint book-running manager, participating in the offering and benefiting from the transaction.
Jul 31, 2026 · 10 articles
4 55
Business
BlossomHill Therapeutics $150M IPO Pricing
Impact: LifeSci Capital participated as a joint book-running manager, gaining underwriting fees and exposure in the biotech IPO market. The deal contributes to its deal flow and industry standing.
Aug 07, 2026 · 8 articles
4 10
Business
Jade Biosciences Prices Public Offering
Impact: LifeSci Capital is acting as a passive book-running manager for the public offering by Altor BioScience.
Jun 03, 2026 · 12 articles
4 10
Business
Enliven Therapeutics Prices $400M Offering
Impact: LifeSci Capital is acting as a passive book-running manager for the public offering by Enliven Therapeutics.
Jun 11, 2026 · 7 articles
4 0
Business
Neurogene $125M Public Offering Priced
Impact: LifeSci Capital is acting as a joint bookrunning manager for Neurogene's public offering.
Jun 30, 2026 · 6 articles
2 10
Business
Dyne Therapeutics upsized public offering
Impact: Acted as joint book-running manager, earning underwriting fees.
Jul 21, 2026 · 6 articles
2 55
Business
Attovia Therapeutics Upsized IPO Pricing
Impact: LifeSci Capital acted as passive book-running manager, participating in the offering and earning associated fees.
Aug 05, 2026 · 15 articles
4 5
Business
Spyre Therapeutics Upsized Public Offering
Impact: LifeSci Capital is acting as a passive bookrunner for the public offering of Spyre Therapeutics' common stock.
Apr 13, 2026 · 7 articles
4 10
Business
Celldex $300M Public Offering Priced
Impact: LifeSci Capital is acting as a co-lead manager for the public offering by Celldex Therapeutics.
Apr 01, 2026 · 6 articles
4 5
Business
Parabilis Medicines Upsized IPO Priced
Impact: LifeSci Capital LLC is acting as a passive bookrunning manager for the initial public offering of Parabilis Medicines.
Jun 10, 2026 · 7 articles
0 0
Business
Immunic to Participate in Investor Conferences
Impact: LifeSci Capital is hosting the SF Biotech Forum where Immunic will attend.
Jul 09, 2026 · 8 articles
2 5
Business
Crescent Biopharma $125M public offering
Impact: LifeSci Capital acted as passive book-running manager for the offering.
Jul 14, 2026 · 7 articles
4 0
Business
Galera and Obsidian Therapeutics Merger
Impact: LifeSci Capital acted as a placement agent in connection with the concurrent private placement financing.
Apr 14, 2026 · 7 articles
Relationships (2)
United States — United States Securities and Exchange Commission ↔ LifeSci Capital
United States — United States Securities and Exchange Commission ↔ LifeSci Capital
ERGEN INTELLIGENCE
Track LifeSci Capital live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.